29.49

7.90% 2.16

Arcutis Biotherapeutics Inc (ARQT)

Overview News Price History Option Chain Financials Why ARQT Down? Discussions Forecast

Arcutis Biotherapeutics Inc stock is traded at $29.49, with a volume of 2.59M. It is up +7.90% in the last 24 hours and up +42.88% over the past month. Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Previous Close:

$27.33

Open:

$27.15

24h Volume:

2.59M

Relative Volume:

1.17

Market Cap:

$3.61B

Revenue:

$59.61M

Net Income/Loss:

$-262.14M

P/E Ratio:

-7.523

EPS:

-3.92

Net Cash Flow:

$-247.49M

1W Performance:

+17.96%

1M Performance:

+42.88%

6M Performance:

+114.32%

1Y Performance:

+187.99%

1-Day Range:

$27.08

$30.01

1-Week Range:

$24.82

$30.01

52-Week Range:

$10.05

$30.01

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name

Arcutis Biotherapeutics Inc

Sector

Healthcare (1129)

Industry

Biotechnology (632)

Phone

805-418-5006

Address

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Employee

342

Twitter

@ArcutisBio

Next Earnings Date

2024-12-06

Latest SEC Filings

ARQT's Discussions on Twitter

Compare ARQT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARQT Arcutis Biotherapeutics Inc	29.49	3.35B	59.61M	-262.14M	-247.49M	-3.92
VRTX Vertex Pharmaceuticals Inc	426.76	107.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	755.90	77.46B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	436.38	58.90B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	918.92	56.55B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	198.76	42.58B	447.02M	-1.18B	-906.14M	-6.1812

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Initiated	Goldman	Neutral
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-28-24	Initiated	Jefferies	Buy
Jan-03-24	Upgrade	Mizuho	Neutral → Buy
Oct-26-23	Downgrade	Mizuho	Buy → Neutral
Oct-13-23	Downgrade	Goldman	Buy → Neutral
Sep-07-22	Initiated	Needham	Buy
Mar-17-22	Initiated	Goldman	Buy
Jun-30-21	Initiated	Mizuho	Buy
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-09-20	Upgrade	Goldman	Neutral → Buy
Oct-08-20	Initiated	Truist	Buy
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight
Feb-25-20	Initiated	Cowen	Outperform
Feb-25-20	Initiated	Goldman	Neutral
Feb-25-20	Initiated	Guggenheim	Buy

View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

Nov 22, 2025

Matsuda Masaru, Arcutis SVP, sells $72k in Arcutis Biotherapeutics stock By Investing.com - Investing.com Canada

Nov 22, 2025

Nov 21, 2025

Responsive Playbooks and the ARQT Inflection - news.stocktradersdaily.com

Nov 21, 2025

Why Arcutis Biotherapeutics Inc. stock appeals to dividend seekersJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com

Nov 21, 2025

Why Arcutis Biotherapeutics Inc. stock is trending among retail tradersFed Meeting & Weekly High Potential Stock Alerts - newser.com

Nov 21, 2025

Why Shares in Arcutis Biotherapeutics Surged Again This Week - sharewise.com

Nov 21, 2025

Arcutis Biotherapeutics director Gilbert sells $455k in stock By Investing.com - Investing.com Canada

Nov 21, 2025

Nov 20, 2025

Is Arcutis Biotherapeutics Inc. stock a buy for dividend growthBuy Signal & Comprehensive Market Scan Insights - newser.com

Nov 20, 2025

Dir Gilbert Files To Sell 16,532 Of Arcutis Biotherapeutics Inc [ARQT] - TradingView

Nov 20, 2025